Topiramate and Pristiq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Topiramate and Pristiq. Common interactions include drug withdrawal syndrome among females and retching among males.

The phase IV clinical study analyzes what interactions people who take Topiramate and Pristiq have. It is created by eHealthMe based on reports of 60 people who take Topiramate and Pristiq from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 26, 2023

60 people who take Topiramate and Pristiq together, and have interactions are studied.

What is Topiramate?

Topiramate has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 40,619 Topiramate users for its effectiveness, alternative drugs and more.

What is Pristiq?

Pristiq has active ingredients of desvenlafaxine succinate. It is often used in depression. eHealthMe is studying from 19,399 Pristiq users for its effectiveness, alternative drugs and more.

Number of Topiramate and Pristiq reports submitted per year:

Common Topiramate and Pristiq drug interactions by gender *:

female:

Drug withdrawal syndrome
Essential tremor
Fall
Fatigue
Fear
Gait disturbance
General physical health deterioration
Grand mal convulsion
Hallucination
Hemiparesis

male:

Retching
Lipids decreased
Dizziness
Dysphonia
Frequent bowel movements
Headache
Infective myositis
Lip swelling
Lung disorder
Mastication disorder

Common Topiramate and Pristiq drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Cerebrovascular accident
Intracranial venous sinus thrombosis
Deep vein thrombosis
Pain
Pulmonary embolism

30-39:

Weight decreased
Alopecia
Blood pressure increased
Chest pain
Constipation
Dyspnoea
Gastrointestinal disorder
Hunger
Hypersensitivity
Injury

40-49:

Injection site pain
Insomnia
Intracranial venous sinus thrombosis
Paranoia
Periarthritis
Peroneal nerve palsy
Phlebitis
Psychotic disorder
Staphylococcal infection
Sudden death

50-59:

Pain in extremity
Abdominal pain upper
Alopecia
Angioedema
Cough
Decreased appetite
Dizziness
Dysgeusia
Dysphonia
Fall

60+:

Constipation
Pneumonia
Increased appetite
Infection parasitic
Multiple fractures
Osteoporosis
Pain in extremity
Suicidal ideation
Tremor
Wrist fracture

Common conditions people have *:

Stress And Anxiety: 8 people, 13.33%
High Blood Pressure: 8 people, 13.33%
Headache (pain in head): 7 people, 11.67%
Pain: 7 people, 11.67%
Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 7 people, 11.67%
Bipolar Disorder (mood disorder): 6 people, 10.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 8.33%
Birth Control: 5 people, 8.33%
Fibromyalgia (a long-term condition which causes pain all over the body): 5 people, 8.33%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 4 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Topiramate and Pristiq?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Topiramate (40,619 reports)
Pristiq (19,399 reports)